Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy

Wenzhen Ge,1 Ning Wu,1 Jessica J Jalbert,1 Ruben GW Quek,1 Jinjie Liu,2 Petra Rietschel,1 Jean-Francois Pouliot,1 James Harnett,1 Melinda Laine Hsu,3 Josephine L Feliciano4 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Genesis Research, LLC, Hoboken, NJ, USA; 3University Hospitals, Clevelan...

Full description

Bibliographic Details
Main Authors: Ge W, Wu N, Jalbert JJ, Quek RGW, Liu J, Rietschel P, Pouliot JF, Harnett J, Hsu ML, Feliciano JL
Format: Article
Language:English
Published: Dove Medical Press 2022-11-01
Series:Cancer Management and Research
Subjects:
immune checkpoint inhibitors
non-small cell lung cancer
pd-l1 expression
real-world data
overall survival
progression-free survival
Online Access:https://www.dovepress.com/real-world-outcomes-and-prognostic-factors-among-patients-with-advance-peer-reviewed-fulltext-article-CMAR

Internet

https://www.dovepress.com/real-world-outcomes-and-prognostic-factors-among-patients-with-advance-peer-reviewed-fulltext-article-CMAR

Similar Items